Delhi HC Denies J&J Relief on ORS Labelling

Introduction On 12 November 2025 the Delhi High Court refused interim relief sought by JNTL Consumer Health (India) Pvt Ltd — a Johnson & Johnson subsidiary — to clear stocks of beverages labelled as “ORSL”. The Food Safety and Standards Authority of India (FSSAI) had issued orders in mid‑October and a reasoned order on 30 October prohibiting the manufacture and sale of ORS‑labelled products that do not comply with World Health Organization (WHO) standards. The court’s refusal, made orally, underscores an acute regulatory‑judicial tension: when does public‑health precaution justify immediate regulatory prohibition, and what is the scope of judicial review of technically specialised administrative decisions?

Legal Background The dispute sits squarely under the Food Safety and Standards Act, 2006 and the Food Safety and Standards (Packaging and Labelling) Regulations, 2011. Under the statutory scheme FSSAI is charged with setting standards and taking remedial action where a food is misbranded, unsafe or otherwise non‑compliant; the Regulations set out labelling and ingredient disclosure requirements (including provisions addressing rehydration solutions and electrolyte replacement products). Indian courts have repeatedly recognised that technical questions of food safety and labelling call for deference to the specialised authority charged with scientific adjudication. See M/S Nestle India Limited v The Food Safety and Standards Authority of India (Bombay High Court, 2015) where the court emphasised the technical domain of FSSAI in labeling and safety matters. At the constitutional level, the precautionary principle and the “polluter pays” doctrine (articulated in Vellore Citizens’ Welfare Forum v Union of India (1996) 5 SCC 647) inform public‑health regulation: uncertainty should not be used as a reason to postpone protective measures.

Critical Analysis Three interlocking legal questions arise: (1) was FSSAI’s order legally tenable and procedurally fair; (2) did the petitioner meet the stringent threshold for interim relief; and (3) how should courts review such regulatory action? On (1), the article reports that FSSAI issued a reasoned order on 30 October — a fact of central importance. Administrative law requires reasoned decisions and an opportunity for affected parties to be heard; where those elements exist, courts will be less inclined to intervene. On (2), interim relief against a regulatory prohibition requires demonstrating a strong prima facie case, irreparable harm and that the balance of convenience favours the petitioner. Regulators acting to prevent potential harm to consumers ordinarily tip the balance against interim clearance of suspect stocks, particularly where scientific uncertainty exists.

Regarding (3), ordinary judicial review principles apply. English administrative law’s Wednesbury unreasonableness test (Associated Provincial Picture Houses Ltd v Wednesbury Corporation [1948] 1 KB 223) and its Indian analogues prescribe narrow grounds for intervention — illegality, irrationality, or procedural impropriety. Indian courts have applied these principles in the food‑safety context by deferring to technical bodies unless the decision is demonstrably perverse. See the Delhi High Court’s approach in Commissioner (Food Safety), GNCTD v Sugandhi Snuff King Pvt Ltd (2023) where the court sustained regulatory action where FSSAI’s technical determinations were supported by evidence.

That said, courts retain an obligation to ensure that the regulator’s scientific basis is not arbitrary. If the company can show that WHO standards were misapplied, that the product conforms to the applicable statutory regime, or that FSSAI ignored its own guidance (for example, FSSAI advisories recommending discretion in minor labelling defects), the petitioner may secure relief on appeal. Important factual gaps remain in reporting: the record does not disclose independent laboratory findings, the precise divergence from WHO standards, the volume and distribution channel of the stocks, or the timeline of compliance efforts — each a material fact in assessing proportionality.

Opinion & Outlook Practically, the Delhi HC’s refusal to grant interim relief signals judicial caution in the face of regulatory action that invokes public health. Courts will continue to defer to FSSAI’s technical competence unless clear legal error, procedural unfairness or patent irrationality is shown. For industry, the ruling reinforces three imperatives: (a) secure contemporaneous scientific testing and accredited lab reports; (b) engage promptly with FSSAI processes (sample submission, rebuttal data, remedial labelling); and (c) where necessary, seek expedited interim relief only on strong evidentiary footing.

Policy‑wise, the episode exposes a regulatory gap. ORS/rehydration‑type labelling occupies a hybrid space between therapeutic claims and ordinary food labelling. To reduce litigation and market disruption, FSSAI should publish a concise, WHO‑aligned guidance clarifying permissible labelling, an expedited compliance testing protocol and a transparent remedial pathway for borderline products. An industry‑regulator fast track for scientific adjudication would reduce the need for protracted court intervention.

Conclusion The Delhi High Court’s refusal reflects the weight courts place on public‑health precaution and technical expertise in food safety disputes. While affected manufacturers retain legal remedies, success will turn on demonstrable compliance with statutory standards and a clear evidentiary showing that regulatory action was disproportionate or procedurally flawed. In the interim, clearer regulatory guidance and faster scientific resolution will serve both public health and commercial certainty.